Happiness Biotech Group Limited logo
Happiness Biotech Group Limited HAPP
report update icon

Quarterly report 2026-Q4
added 08-14-2026

Happiness Biotech Group Limited Financial Ratios 2026-2011 | HAPP

Brief overview of Happiness Biotech Group Limited's financial ratios

This overview follows the five latest available observations from 2019 through 2022.

Market valuation is represented by P/S 0.43x (median 0.43x), P/B 0.12x (median 0.3x). Multiples are on average 30.8% below their own medians. Shares look cheaper than their recent historical valuation.

Current measures of operating quality are ROE -32.5%, ROA -22.2%, ROCE -27.8%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.

Valuation takeaway

Happiness Biotech Group Limited's discount may reflect genuine profitability issues rather than market inefficiency alone.

Annual Financial Ratios Happiness Biotech Group Limited

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- - - - -0.2 - 1.9 4.9 - - - - - - - -

P/S

- - - - 0.4 - 0.4 1.4 - - - - - - - -

EPS

- - 0.8 -12.6 -1.2 0.0 0.5 0.8 0.8 - - - - - - -

EV (Enterprise Value)

-6.44 M 6.3 M 2.22 M 19.1 M 9.18 M -21.5 M -4.3 M 82 M -40.1 K 18.2 M - - - - - -

EBITDA per Share

- - -0.82 -0.7 -0.27 0.09 0.67 0.98 - - - - - - - -

EV/EBITDA

0.5 -1.0 -0.6 -4.8 -0.8 - 2.3 - - - - - - - - -

PEG

- - - - - - -0.16 - - - - - - - - -

P/B

- - - - 0.1 - 0.3 1.5 - - - - - - - -

P/CF

- - - - -0.8 - 2.2 14.1 - - - - - - - -

ROE %

-40.75 -32.54 -181.45 -486.07 -62.46 0.83 15.94 30.73 - - - - - - - -

ROA %

-34.54 -22.19 -131.02 -197.41 -50.09 0.70 14.91 28.51 - - - - - - - -

ROCE %

-44.94 -27.78 -76.51 -24.60 -14.29 1.61 19.35 35.86 - - - - - - - -

Current Ratio

9.6 5.4 3.0 1.6 4.9 7.5 15.5 13.8 - - - - - - - -

DSO

5.5 29.0 - - 545.2 164.9 174.0 91.4 - - - - - - - -

DIO

11.6 1907.0 - - 28.3 13.1 21.1 11.3 - - - - - - - -

DPO

47.4 5060.3 - - 186.9 35.6 16.9 9.6 - - - - - - - -

Operating Cycle

17.0 1935.9 - - 573.4 178.0 195.1 102.7 - - - - - - - -

Cash Conversion Cycle

-30.4 -3124.4 - - 386.5 142.4 178.2 93.1 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Happiness Biotech Group Limited

2026-Q4 2026-Q2 2025-Q2 2025-Q1 2024-Q4 2024-Q1 2023-Q4 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- - - - - 0.75 - -0.48 -12.63 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - -0.04 - - -0.82 - 2.7 -0.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-41.31 -222.77 -401.29 -881.46 -848.92 -181.45 - -181.41 -486.07 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-29.30 -160.32 -331.89 -524.02 -501.83 -131.02 - -173.40 -197.41 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-34.24 -110.76 -3.55 -24.31 3.47 -76.51 - 104.58 -24.60 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

5.4 4.2 9.7 5.4 3.0 3.0 4.9 22.6 1.6 - - - - - - - 7.5 - 15.9 - 15.4 - - - 13.8 - - - 6.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- 7.3 - - - - - 0.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

- 2.7 503.7 476.7 - - - 2.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

- 12.2 1336.7 1265.1 - - - 231.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Happiness Biotech Group Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.49 1.0 % $ 6.04 B israelIsrael
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.07 0.45 % $ 114 M britainBritain
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 2.18 0.93 % $ 1.47 B israelIsrael
Zymeworks Zymeworks
ZYME
$ 26.21 4.21 % $ 1.35 B canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Mersana Therapeutics Mersana Therapeutics
MRSN
- - $ 3.56 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Morphic Holding Morphic Holding
MORF
- - $ 2.42 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
Theravance Biopharma Theravance Biopharma
TBPH
$ 17.03 0.03 % $ 857 M cayman-islandsCayman-islands
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 76.99 0.03 % $ 997 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA